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Abstract The Ras homology (Rho) guanine nucleotide ex-
change factor p115-RhoGEF couples the K13 heterotrimeric
guanine nucleotide binding protein (G protein) subunit to Rho
GTPase. K13 binds to a regulator of G protein signaling (RGS)
domain in p115-RhoGEF, but the mechanism of K13 activation
of p115-RhoGEF is poorly understood. In this report, we dem-
onstrate in cell-based assays that the acidic-rich N-terminus,
adjacent to the RGS domain, is required for binding to activated
K13, and re¢ne the importance of this region by showing that
mutation of glutamic acids 27 and 29 in full-length p115-Rho-
GEF is su⁄cient to prevent interaction with activated K13. How-
ever, K13-interacting de¢cient N-terminal mutants of p115-Rho-
GEF retain K13-dependent plasma membrane recruitment.
Overall, these ¢ndings demonstrate a critical role for the
N-terminal extension of p115-RhoGEF in mediating binding
to K13 and dissociate two activities of p115-RhoGEF: binding
to activated K13 and translocation to the PM in response to
activated K13.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Heterotrimeric guanine nucleotide binding proteins (G pro-
teins) (KLQ) function as molecular switches to couple activated
heptahelical G protein-coupled receptors (GPCRs) to a vari-
ety of intracellular e¡ectors. The heterotrimeric G protein K
subunits are typically divided into four families, Ks, Ki, Kq,
and K12, based on sequence and functional similarities. K12
and K13, which comprise the K12 family and share 65% amino
acid identity, have been implicated in the regulation of cell
growth, oncogenesis, cell morphological changes, and actin
cytoskeleton rearrangements [1]. Some of these activities, par-
ticularly actin cytoskeleton rearrangements, are mediated by
the Ras homology (Rho) family of small GTPases [2]. Rho is
activated by members of a large family of proteins, termed
Rho guanine nucleotide exchange factors (RhoGEF) [3], and
one RhoGEF, called p115-RhoGEF, has been demonstrated
to provide a direct link between K13 and Rho [4,5].
Like virtually all RhoGEFs, p115-RhoGEF contains a tan-
dem Dbl homology/pleckstrin homology (DH/PH) domain.
The DH domain catalyzes the exchange of guanosine triphos-
phate (GTP) for guanosine diphosphate (GDP) on Rho, while
the PH domain is necessary for both DH domain activity [6]
and regulated plasma membrane (PM) localization [7]. Using
reconstitution of puri¢ed components, it has been clearly
demonstrated that activated forms of K13 can directly stimu-
late the Rho exchange activity of p115-RhoGEF [4]. More-
over, inside cells, activated K13 or GPCRs that activate K13
can recruit p115-RhoGEF from the cytoplasm to the PM [6^
8].
The connection between K13 and p115-RhoGEF is medi-
ated, at least in part, by an N-terminal regulator of G protein
signaling (RGS) domain found in p115-RhoGEF that pro-
vides a binding site for K13 [4,9^11]. More than 20 RGS pro-
teins have been identi¢ed, and they share an approximately
120 amino acid conserved domain [12]. The RGS domain of
p115-RhoGEF is required for K13-mediated activation of its
RhoGEF activity and for K13-dependent PM recruitment
[7,10,11]. In addition, most RGS proteins function to accel-
erate the intrinsic GTP hydrolysis activity of select G protein
K subunits, and, indeed, the RGS domain of p115-RhoGEF is
a GTPase activating protein (GAP) for K12 and K13 [5]. Thus,
p115-RhoGEF is both an e¡ector and negative regulator of
K13. Two additional RhoGEFs, PDZ-RhoGEF and LARG,
also contain an RGS domain and may also be involved in
coupling K12=13 to Rho [9,13^16]. The RGS domains of
P115-RhoGEF, PDZ-RhoGEF and LARG show very weak
identity to other RGS boxes, and crystal structures of RGS
domains from p115-RhoGEF and PDZ-RhoGEF show that
these RGS domains require an additional V60 C-terminal
amino acids to form the structural RGS domain [17,18].
For these reasons, the RGS domains from the RhoGEFs
have been termed RGSL, for RGS-like, or rgRGS, for Rho-
GEF RGS, domains.
In p115-RhoGEF, the core RGS domain consists of amino
acids 44^233, as de¢ned by structural analysis [17]. However,
a recent study demonstrated that some portion of the N-ter-
minal 42 amino acids is also critical for RGS domain func-
tion. Whereas an rgRGS domain consisting of amino acids 1^
252 of p115-RhoGEF functions as a GAP for K13, a 42^252
rgRGS domain loses its GAP activity although it partially
retains the ability to bind activated K13 [10]. The experiments
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described in this report were designed to test whether the
N-terminal extension of p115-RhoGEF’s rgRGS domain af-
fects the ability of full-length p115-RhoGEF to interact with
K13 in cell lysates or intact cells. We demonstrate that deletion
of p115-RhoGEF amino acids 1^31 abolishes the ability of
p115-RhoGEF to co-immunoprecipitate with activated K13.
Furthermore, we show that mutation of glutamic acids 27
and 29 also blocks co-immunoprecipitation of p115-RhoGEF
and K13. Surprisingly, however, the N-terminal V40 amino
acid extension is not required for strong K13-induced PM re-
cruitment of p115-RhoGEF.
2. Materials and methods
2.1. Plasmids
The N-terminal Myc epitope (MEQKLISEED)-tagged p115-Rho-
GEF in pcDNA3 has been described [7,8]. The HA epitope-tagged
(DVPDYA) pcDNA3HA GK13wt and pcDNA3HA GK13QL, con-
taining the GTPase inhibiting Q226L mutation, were provided by
J.S. Gutkind [14]. For generation of N-terminal deletions of p115-
RhoGEF, Myc epitope-tagged fragments of p115-RhoGEF were am-
pli¢ed with forward and reverse primers containing a 5P HindIII site
and a 3P XbaI site for subcloning into pcDNA3. The Stratagene
QuikChange site-directed mutagenesis kit was used to replace the
glutamates at positions 27 and 29, 34 and 36, and 40 and 41 with
alanines to generate pcDNA3-Myc-p115(E27,29A), pcDNA3-Myc-
p115(E34,36A) and pcDNA3-Myc-p115(E40,41A), respectively. The
forward and reverse primers used were 5P-ggggctgcggatgcggat-3P and
5P-atccgcatccgcagcccc-3P for p115(E27,29A); 5P-gattttgcgaacgcgctg-3P
and 5P-cagcgcgttcgcaaaatc-3P for P115(E34,36A); and 5P-aactcag-
cagcgcaaaac-3P and 5P-gttttgcgctgctgagtt-3P for p115(E40,41A). The
correct DNA sequence of the mutants was con¢rmed by DNA se-
quencing of the entire open reading frame (Kimmel Cancer Center
Nucleic Acid Facility).
2.2. Cell culture and transfection
HEK293 and COS cells were grown in Dulbecco’s modi¢ed Eagle’s
medium containing 10% fetal bovine serum (FBS) and penicillin and
streptomycin. Cells were seeded in 6 cm or six-well plates 24 h prior to
transfection. Transient transfections were performed with FuGene 6
(Roche Molecular Biochemicals) according to the manufacturer’s pro-
tocol.
2.3. Antibodies
The anti-HA mouse monoclonal antibody 12CA5 was from Roche
Molecular Biochemicals, and the anti-Myc mouse monoclonal anti-
body 9E10 was from Covance. An anti-HA rabbit polyclonal anti-
body was from Santa Cruz Biotechnology. Goat anti-mouse and goat
anti-rabbit secondary antibodies conjugated to Alexa 488 and Alexa
594, respectively, were from Molecular Probes.
2.4. Immunoprecipitations and immunoblotting
Co-immunoprecipitation analyses were performed as described
[7,8]. Brie£y, 72 h after transfection, COS cells were lysed in 500 Wl
lysis bu¡er (25 mM HEPES, pH 7.5, 150 mM NaCl, 2.5 mM MgCl2,
1 mM ethylenediamine tetraacetic acid (EDTA), 1% Triton X-100,
0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl £uoride, 20
Wg/ml aprotinin, 20 Wg/ml leupeptin, 20 mM L-glycerophosphate, and
1 mM sodium vanadate). After incubation on ice for 1 h, cell suspen-
sions were centrifuged at 1500Ug for 5 min at 4‡C. For AlF34 experi-
ments, the supernatants were collected and divided into two aliquots.
One aliquot was treated with 20 WM AlCl3 and 20 mM NaF (+AlF34 )
and the other part was untreated (3AlF34 ). 9E10 or 12CA5 antibodies
were added, and incubations were carried out for 1 h at 4‡C. The
immunocomplexes were recovered with the aid of Protein A/G aga-
rose (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Pro-
teins in cell lysates and the immunocomplexes were resolved by so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and analyzed by immunoblotting.
2.5. Subcellular fractionation
Subcellular fractionation was performed as described previously
[7,8]. 48 h after transfection, HEK293 cells were lysed in hypotonic
bu¡er and separated into membrane-rich particulate (P) and cytoplas-
mic soluble (S) fractions by centrifuging the lysates at 100 000Ug for
20 min as described. Equal volumes (i.e. equivalent cell fractions) of
particulate (P) and soluble (S) fractions were loaded on SDS^PAGE
for immunoblotting.
2.6. Immuno£uorescence microscopy
HEK293 cells were grown on coverslips placed in six-well plates
and were transfected with appropriate plasmids as described in the
¢gure legends. 24 h after transfection, the cells were ¢xed with 3.7%
formaldehyde in phosphate-bu¡ered saline (PBS) for 15 min and per-
meabilized by incubation in blocking bu¡er (2.5% non-fat milk and
1% Triton X-100 in triethanolamine-bu¡ered saline (TBS)) for 30 min.
Cells were then incubated with 5 Wg/ml anti-myc mouse monoclonal
antibody 9E10 and a 1:100 dilution of anti-HA rabbit polyclonal
antibody in blocking bu¡er for 1 h. The cells were washed with block-
ing bu¡er and incubated with a 1:100 dilution of goat anti-mouse
Alexa 488 antibodies and goat anti-rabbit Alexa 594 secondary anti-
bodies for 30 min. The coverslips were washed with 1% Triton X-100/
TBS, rinsed in distilled water, and mounted on glass slides with 10 Wl
of Prolong Antifade reagent (Molecular Probes, Inc.). Images were
viewed with an Olympus BX60 microscope equipped with a 60U/
NA1.4 objective. Images were recorded with a Sony DKC-5000 digital
camera and transferred to Adobe Photoshop for digital processing.
3. Results
3.1. N-terminal deletion mutants of p115-RhoGEF are defective
in co-immunoprecipitation with AlF34 -activated K13
To examine a role for the N-terminal extension (Fig. 1) in
binding of full-length p115-RhoGEF to activated K13, we gen-
erated a series of short deletions at the N-terminus, (22-
912)p115, (32-912)p115, and (42-912)p115, in which 21, 31,
and 41 amino acids, respectively, were removed. We ¢rst
tested the ability of the N-terminal deletion mutants of
p115-RhoGEF to interact with K13, as measured by AlF34 -
dependent co-immunoprecipitation [7,8,10]. Co-immunopreci-
pitations were performed in a reciprocal manner. Immunopre-
cipitation with anti-Myc antibody tested the ability of Myc-
tagged p115-RhoGEF or the various deletion mutants to ‘pull
down’ K13 (Fig. 2A), while immunoprecipitation using anti-
HA antibody tested the ability of HA-tagged K13 to ‘pull
down’ p115-RhoGEF or its mutants (Fig. 2B). As shown
previously [7,8,10], full-length p115-RhoGEF and K13 co-im-
munoprecipitated from lysates treated with AlF34 (Fig. 2A
and B, lanes 1 and 5), but little or no co-immunoprecipitation
was observed in the absence of AlF34 activation of K13 (Fig. 2A
and B, lanes 1 and 5). With the N-terminal deletion mutants,
only (22-912)p115 (Fig. 2A and B, lane 2), but not (32-
Fig. 1. p115-RhoGEF schematic and N-terminal amino acid se-
quence. A: A representation of the domain structure of p115-Rho-
GEF is presented. Amino acid numbering and the location of crit-
ical domains are indicated. The rgRGS domain is de¢ned by
structural analysis [17] while the DH and PH domains are de¢ned
by sequence comparisons [22] and functional analysis [6]. B: Se-
quence of amino acids 1^42 is indicated. Glutamic acids mutated to
alanines in this study are underlined.
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912)p115 or (42-912)p115 (Fig. 2A and B, lanes 3 and 4), co-
immunoprecipitated with K13 from lysates treated with
(+) AlF34 , suggesting that the 10 amino acids, 22^31, pre-
ceding the rgRGS domain (Fig. 1) are required for K13 bind-
ing.
3.2. Glutamic acids 27 and 29 of p115-RhoGEF are essential
for binding to activated K13
The short N-terminal extension prior to the rgRGS core
domain contains an acidic stretch at amino acids 27^42
(Fig. 1). To further test the role of these acidic residues at
the N-terminus, we generated mutants of p115-RhoGEF,
where glutamic acids at positions 27 and 29, 34 and 36, and
40 and 41, were mutated dually with alanine residues, to gen-
erate p115(E27,29A), p115(E34,36A) and p115(E40,41A), re-
spectively (Fig. 1). We observed virtually no co-immunopre-
cipitation of p115(E27,29A) with K13 in the presence of AlF34
(Fig. 2A and B, lane 6). On the other hand, marked AlF34 -
dependent co-immunoprecipitation of p115(E34,36A) and
p115(E40,41A) with K13 was detected, similar to full-length
p115-RhoGEF (Fig. 2A and B, lanes 7 and 8). These experi-
ments re¢ne the initial N-terminal deletions and indicate that
one or both of glutamic acids 27 and 29 are critical for p115-
RhoGEF to interact with K13. Although the acidic-rich region
extends beyond glutamic acids 27 and 29, mutation of gluta-
mic acids 34, 36, 40 and 41 had no e¡ect on the ability of
p115-RhoGEF to interact with activated K13.
3.3. N-terminal mutants of p115-RhoGEF retain strong
K13-promoted PM recruitment
We next examined the ability of a constitutively active mu-
tant of K13, K13QL, to induce cytoplasm to PM redistribution
of the N-terminal mutants of p115-RhoGEF. As we demon-
strated previously [8], full-length p115-RhoGEF is found dis-
tributed throughout the cytoplasm (Fig. 3A, a), but, when
K13QL is co-expressed, p115-RhoGEF strongly localizes to
the PM (Fig. 3A, b). Moreover, we demonstrated recently
[7] that deletion of amino acids 1^245, which includes the
rgRGS core domain and the N-terminal extension of p115-
RhoGEF, completely prevented co-immunoprecipitation with
activated K13 and abolished K13-promoted recruitment to the
PM (Fig. 3A, c and d). Thus, results with (246-912)p115 [7]
suggested a correlation between loss of binding to K13 and loss
of PM recruitment by K13. In contrast, the K13 binding-defec-
tive N-terminal extension mutants showed a surprising reten-
tion of K13-promoted PM recruitment. All the mutants were
cytoplasmic when expressed alone (Fig. 3A, e and g; and not
shown). When co-expressed with K13QL, p115(E27,29A)
(Fig. 3A, f) and (42-912)p115 (Fig. 3A, h) displayed strong
PM localization, as did (22-912)p115, (32-912)p115, p115
(E34,36A) and p115(E40,41A) (not shown).
To extend the immuno£uorescent microscopy results, sub-
cellular fractionation into soluble (S) and membrane-rich par-
ticulate (P) fractions was performed. As shown previously [8],
p115-RhoGEF was detected almost exclusively in the ‘S’ frac-
Fig. 2. Co-immunoprecipitation of AlF34 -activated K13 and N-terminal mutants of p115-RhoGEF. COS cells were transfected with plasmids en-
coding HA-tagged wild type K13 (2 Wg) along with Myc-tagged p115-RhoGEF (p115) or the indicated N-terminal mutants of p115-RhoGEF
(0.5 Wg). Cell lysates were either not treated (3) or treated (+) with AlF34 , as described in Section 2. A: Myc epitope-tagged proteins were im-
munoprecipitated using an anti-Myc monoclonal antibody and the immunocomplexes were immunoblotted using an anti-HA monoclonal anti-
body. B: In a separate set of transfections, identical to A, HA epitope-tagged wild type K13 was immunoprecipitated using anti-HA monoclonal
antibody and the complexes were immunoblotted using an anti-Myc monoclonal antibody. The bands corresponding to the asterisk (*) repre-
sent precipitated immunoglobulin. C: The cell lysates from each transfection were immunoblotted using an anti-Myc monoclonal antibody to
determine expression levels of p115-RhoGEF (lanes 1 and 5), (22-912)p115 (lane 2), (32-912)p115 (lane 3), (42-912)p115 (lane 4),
p115(E27,29A) (lane 6), p115(E34,36A) (lane 7), and p115(E40,41A) (lane 8). D: The same blots from C were re-probed with an anti-HA
monoclonal antibody to detect expression levels of K13 (lanes 1^8). The experiments in A^D are representatives of three similar independent ex-
periments.
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tion when expressed with empty vector (Fig. 3B, lanes 1P and
1S) in HEK293 cells. However, a signi¢cant amount of p115-
RhoGEF distributed into the ‘P’ fractions when expressed
with K13QL (Fig. 3B, lanes 2P and 2S), as expected [7,8].
Similarly, N-terminal extension mutants shifted from the ‘S’
to ‘P’ fraction upon K13QL co-expression. As shown in Fig.
3B, (22-912)p115 and (42-912)p115 displayed substantial par-
titioning into the membrane-rich particulate ‘P’ fractions
when co-expressed with K13QL (Fig. 3B, lanes 3P and 3S,
and lanes 4P and 4S). Taken together, the immuno£uores-
cence microscopy (Fig. 3A) and cell fractionation (Fig. 3B)
results indicate that the 41 amino acid N-terminal extension is
not required for K13QL-mediated PM translocation of p115-
RhoGEF.
Deletion or mutation of residues in the N-terminal exten-
sion of p115-RhoGEF had no e¡ect on Rho-dependent sig-
naling (not shown), as measured by a serum response factor
(SRF) transcriptional reporter assay. The N-terminal mutants
and wild type full-length p115-RhoGEF displayed similar lev-
els of basal activation of an SRF-luciferase reporter (not
shown), indicating that N-terminal deletion or mutation did
not disable the intrinsic Rho exchange activity. Unfortunately,
we were unable to demonstrate whether or not activated K13
could e¡ect an increase in activity of both wild type p115-
RhoGEF and the N-terminal mutants of p115-RhoGEF in-
side cells, since we and others have been unable to demon-
strate a synergistic activation of SRF transcription by com-
bined expression of K13QL and p115-RhoGEF [16,19].
Moreover, we have measured activation of RhoA directly us-
ing a well-described Rho pull-down assay [20], but, like the
Fig. 3. Amino acids 1^41 are not required for K13QL-mediated PM targeting of p115-RhoGEF. A: HEK293 cells were transfected with plas-
mids encoding full-length p115-RhoGEF (FL-p115) (a and b), (246-912)p115 (c and d), p115(E27,29A) (e and f) or (42-912)p115 (g and h)
(0.05 Wg), along with either empty pcDNA3 (a, c, e and g) or with a plasmid encoding K13QL (b, d, f and h) (0.5 Wg). Cells on coverslips were
¢xed and prepared for immuno£uorescence microscopy as described in Section 2. Subcellular localization of p115-RhoGEF and N-terminal mu-
tants was visualized by indirect immuno£uorescence using an anti-Myc monoclonal antibody. Cells were also co-stained with an anti-HA poly-
clonal antibody to identify the cells expressing K13QL (not shown). More than 100 cells were examined in at least three experiments and
s 95% cells showed staining patterns similar to the images presented. Bar, 10 Wm. B: HEK293 cells in 6 cm plates were transfected with plas-
mids encoding full-length p115-RhoGEF (p115), (22-912)p115 or (42-912)p115 along with empty pcDNA3 (3) or pcDNA3 encoding K13QL
(+). After lysis in hypotonic bu¡er, cell lysates were separated into soluble (S) and particulate (P) fractions, as described in Section 2. The frac-
tions were immunoblotted with an anti-Myc monoclonal antibody. C: Expression of p115-RhoGEF (lanes 1 and 2), (22-912)p115 (lanes 3 and
4) and (42-912)p115 (lanes 5 and 6) was determined by an immunoblot of cell lysates (from B) using an anti-Myc monoclonal antibody. D: Im-
munoblot in C was re-probed with an anti-HA monoclonal antibody to detect expression of K13QL (lanes 2, 4 and 6). Experiments in B^D are
representatives of three independent subcellular fractionation analyses.
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SRF assay, we have not detected any synergistic activation of
RhoA by combined expression of K13QL and p115-RhoGEF
(not shown).
3.4. N-terminal mutants of p115-RhoGEF are defective in
co-immunoprecipitation with constitutively active K13QL
An important di¡erence between the co-immunoprecipita-
tion assays (Fig. 2) and the subcellular localization assays
(Fig. 3) is that AlF34 -activated K13 was used in the former,
while the constitutively active K13QL mutant was used in the
latter. K13QL is a mutant lacking GTPase activity and there-
fore locked in a GTP-bound active form; however, AlF34 -
activated K13 is thought to mimic the transition state of
GTP hydrolysis. Therefore, we tested the ability of K13QL
to interact, via co-immunoprecipitation, with p115-RhoGEF
or the N-terminal deletion mutants of p115-RhoGEF. We
detected co-immunoprecipitation of K13QL with p115-Rho-
GEF and (22-912)p115 but not with (32-912)p115 or (42-
912)p115, both in anti-Myc immunoprecipitates (Fig. 4A)
or in anti-HA immunoprecipitates (Fig. 4B). Similarly,
p115(E27,29A) displays little or no co-immunoprecipitation
with K13QL, while p115(E34,36A) interacts with K13QL (Fig.
4E). Note that in one co-immunoprecipitation experiment
(Fig. 4A), but not the reciprocal one (Fig. 4B), an apparent
weak interaction between K13QL and (32-912)p115 is ob-
served, although it is not above the basal level of co-immu-
noprecipitation of wild type K13 and full-length p115-Rho-
GEF (Fig. 4A). A small degree of apparently activation-
independent, or basal, interaction of wild type K13 and full-
length p115-RhoGEF is typically observed in these co-immu-
noprecipitation assays (Fig. 4) [10] ; this may represent wild
type K13 binding to a non-RGS site on p115-RhoGEF or may
re£ect the presence of trace amounts of activating aluminum
and £uoride in the samples. Importantly, the co-immunopre-
cipitation results using K13QL further con¢rm that the N-ter-
minal residues of p115-RhoGEF are critical for its binding to
active K13.
4. Discussion
In this report, we demonstrate that an acidic-rich region
contained within the V40 amino acid N-terminal extension
of p115-RhoGEF is essential for binding to activated K13.
Deletion analysis determined that amino acids 22^31 encom-
passed a critical region for allowing p115-RhoGEF to interact
with K13, and, moreover, mutational analysis demonstrated
that mutation of glutamic acids 27 and 29 together was su⁄-
cient to prevent p115-RhoGEF from binding to K13, as mea-
sured in co-immunoprecipitation assays. In addition, we
present the surprising result that K13 binding de¢cient N-ter-
minal mutants of p115-RhoGEF retain K13-mediated recruit-
ment from the cytoplasm to PM, demonstrating a clear sep-
aration of these two activities of p115-RhoGEF: binding to
activated K13 and translocation to the PM in response to
activated K13.
The studies described here, taken together with the recent in
vitro studies using the isolated rgRGS domain reported by
Wells et al. [10], de¢ne a novel aspect of the RGS domain
of p115-RhoGEF compared to other RGS proteins. Although
all RGS proteins share a conserved RGS core domain, they
contain variable sequences and domains outside the RGS box
[21] that in£uence subcellular localization and signaling spec-
i¢city. However, for p115-RhoGEF, the N-terminal extension
outside of the structurally de¢ned rgRGS domain [17,18] ap-
pears to be required for interaction with its G protein binding
partner, K13. The exact mechanism of how the N-terminal
acidic-rich region contributes to K13 binding is presently un-
clear. The acidic side chains may de¢ne a novel contact site
for K13 or they may be necessary to maintain a conformation
of the rgRGS domain that is competent to bind K13. The
Fig. 4. Co-immunoprecipitation of constitutively active K13QL and
N-terminal mutants of p115-RhoGEF. COS cells were transfected
with plasmids encoding full-length p115-RhoGEF (p115) or the in-
dicated N-terminal deletion or point mutants (0.5 Wg) along with
plasmids encoding either wild type K13 or K13QL (2 Wg), as indi-
cated. A: Myc epitope-tagged p115-RhoGEF and the N-terminal
deletion mutants were immunoprecipitated from cell lysates using an
anti-Myc monoclonal antibody. The immunoprecipitates were immu-
noblotted and probed with an anti-HA monoclonal antibody. B: In
a separate experiment, COS cells were transfected in an identical
manner as described above. HA-tagged wild type K13 or K13QL
were immunoprecipitated from cell lysates using anti-HA monoclo-
nal antibody. The complexes were immunoblotted using anti-Myc
monoclonal antibody. The bands corresponding to the asterisk (*)
indicate precipitated heavy chain of immunoglobulin. C: The cell ly-
sates used as the input for the immunoprecipitation in A were im-
munoblotted using an anti-HA monoclonal antibody to determine
expression levels of K13 (lanes 1, 3, 5, and 7) or K13QL (lanes 2, 4,
6, and 8). D: The cell lysates used as the input for the immunopre-
cipitation in B were immunoblotted using an anti-myc monoclonal
antibody to determine expression levels of p115-RhoGEF (lanes 1
and 2), (22-912)p115 (lanes 3 and 4), (32-912)p115 (lanes 5 and 6),
and (42-912)p115 (lanes 7 and 8). E: Myc epitope-tagged
p115(E27,29A) (lanes 1 and 2) and p115(E34,36A) (lanes 3 and 4)
were immunoprecipitated from cell lysates using an anti-Myc mono-
clonal antibody. The immunoprecipitates were immunoblotted and
probed with an anti-HA monoclonal antibody to detect K13 (lanes 1
and 3) and K13QL (lanes 2 and 4). F: The cell lysates used as the
input for the immunoprecipitation in E were immunoblotted using
an anti-HA monoclonal antibody to determine expression levels of
K13 (lanes 1 and 3) and K13QL (lanes 2 and 4).
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recently solved crystal structure of the rgRGS domain of
p115-RhoGEF [17] utilized residues 42^252, and it was re-
ported that the rgRGS domain failed to crystallize when it
contained the N-terminal 41 amino acids. Thus, the N-termi-
nal extension is likely £exible, at least in the absence of K13,
and is not intrinsically required for the stability of the rgRGS
core domain. Interestingly, we note that a number of acidic
residues are present immediately N-terminal to the rgRGS
core domains of PDZ-RhoGEF and LARG, two other Rho-
GEFs that interact with K13.
Although the mutants (42-912)p115, (32-912)p115 and
p115(E27,29A) displayed very little or no interaction with
either AlF34 -activated K13 or the constitutively activated
K13QL, these mutants completely retained K13-promoted
membrane recruitment, as measured by immuno£uorescence
microscopy and subcellular fractionation. At least two alter-
native mechanisms, not necessarily mutually exclusive, may
explain this apparent paradox. First, weak interactions be-
tween the rgRGS domain of p115-RhoGEF and K13QL, not
evident in co-immunoprecipitation experiments, may su⁄ce to
bring the N-terminal mutants to the PM where additional
membrane localization mechanisms can compensate for de-
creased binding to K13. For example, we recently demon-
strated, by deletion analysis, that p115-RhoGEF’s PH domain
is crucial for strong PM targeting [7] ; binding of the PH
domain to membrane lipids or proteins may allow tight PM
binding, even when interaction with K13 is disrupted as seen
with the N-terminal mutants of p115-RhoGEF. Consistent
with the possibility that p115-RhoGEF mutants retain a
weak interaction with K13, a domain of p115-RhoGEF con-
sisting of amino acids 42^252 retains 10^20% of the K13 bind-
ing ability of a 1^252 rgRGS fragment [10], and, in some
cases, we could detect a small level of co-immunoprecipitation
of K13QL and mutants such as (32-912)p115 (Fig. 4A). Alter-
natively, our results are consistent with the presence of an
additional binding site for K13 on p115-RhoGEF. Recent re-
ports have suggested the presence of such an additional inter-
action site [7,10] that is revealed only upon combined N- and
C-terminal truncation of p115-RhoGEF. In this model, the
secondary interaction site for K13 must function in concert
with the rgRGS domain, since deletion of the complete
N-terminus, consisting of the N-terminal extension and
rgRGS domain, results in a p115-RhoGEF deletion mutant
that is refractory to K13-dependent PM recruitment (Fig. 3A, c
and d) [7] and to K13 stimulation of Rho exchange activity in
vitro [10]. Although the mechanistic basis remains unclear for
K13 activation of the Rho exchange activity of p115-RhoGEF,
the work presented in this report provides new insight into the
determinants responsible for the interaction of K13 and p115-
RhoGEF.
Acknowledgements: The authors thank Christopher Fischer for excel-
lent technical assistance. This work was supported by NIH grant
GM62884 (to P.B.W.), a grant from the W.W. Smith Charitable Trust
(to P.B.W.), and a fellowship from the American Heart Association
Pennsylvania-Delaware A⁄liate (to R.B.).
References
[1] Radhika, V. and Dhanasekaran, N. (2001) Oncogene 20, 1607^
1614.
[2] Buhl, A.M., Johnson, N.L., Dhanasekaran, N. and Johnson,
G.L. (1995) J. Biol. Chem. 270, 24631^24634.
[3] Schmidt, A. and Hall, A. (2002) Genes Dev. 16, 1587^1609.
[4] Hart, M.J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W.D.,
Gilman, A.G., Sternweis, P.C. and Bollag, G. (1998) Science
280, 2112^2114.
[5] Kozasa, T., Jiang, X., Hart, M.J., Sternweis, P.M., Singer, W.D.,
Gilman, A.G., Bollag, G. and Sternweis, P.C. (1998) Science 280,
2109^2111.
[6] Wells, C.D., Gutowski, S., Bollag, G. and Sternweis, P.C. (2001)
J. Biol. Chem. 276, 28897^28905.
[7] Bhattacharyya, R. and Wedegaertner, P.B. (2003) Biochem. J., in
press.
[8] Bhattacharyya, R. and Wedegaertner, P.B. (2000) J. Biol. Chem.
275, 14992^14999.
[9] Fukuhara, S., Chikumi, H. and Gutkind, J.S. (2001) Oncogene
20, 1661^1668.
[10] Wells, C.D., Liu, M.Y., Jackson, M., Gutowski, S., Sternweis,
P.M., Rothstein, J.D., Kozasa, T. and Sternweis, P.C. (2002)
J. Biol. Chem. 277, 1174^1181.
[11] Mao, J., Yuan, H., Xie, W. and Wu, D. (1998) Proc. Natl. Acad.
Sci. USA 95, 12973^12976.
[12] Ross, E.M. and Wilkie, T.M. (2000) Annu. Rev. Biochem. 69,
795^827.
[13] Fukuhara, S., Chikumi, H. and Gutkind, J.S. (2000) FEBS Lett.
485, 183^188.
[14] Fukuhara, S., Murga, C., Zohar, M., Igishi, T. and Gutkind, J.S.
(1999) J. Biol. Chem. 274, 5868^5879.
[15] Kourlas, P.J. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 2145^
2150.
[16] Suzuki, N., Nakamura, S., Mano, H. and Kozasa, T. (2003)
Proc. Natl. Acad. Sci. USA 100, 733^738.
[17] Chen, Z., Wells, C.D., Sternweis, P.C. and Sprang, S.R. (2001)
Nat. Struct. Biol. 8, 805^809.
[18] Longenecker, K.L., Lewis, M.E., Chikumi, H., Gutkind, J.S. and
Derewenda, Z.S. (2001) Structure (Cambridge) 9, 559^569.
[19] Sagi, S.A., Seasholtz, T.M., Kobiashvili, M., Wilson, B.A.,
Toksoz, D. and Brown, J.H. (2001) J. Biol. Chem. 276, 15445^
15452.
[20] Ren, X.D. and Schwartz, M.A. (2000) Methods Enzymol. 325,
264^272.
[21] Hepler, J.R. (1999) Trends Pharmacol. Sci. 20, 376^382.
[22] Hart, M.J., Sharma, S., elMasry, N., Qiu, R.G., McCabe, P.,
Polakis, P. and Bollag, G. (1996) J. Biol. Chem. 271, 25452^
25458.
FEBS 27126 26-3-03
R. Bhattacharyya, P.B. Wedegaertner/FEBS Letters 540 (2003) 211^216216
